Obesity

Company announces publication of oleoyl estrone's human use

Published in Obesity and Diabetes Week, December 15th, 2003

Manhattan Pharmaceuticals, Inc., (MHTT) announced the first, peer-reviewed publication reporting human physiologic responses to its lead product candidate, oleoyl estrone.

This case report, published in Medical Clinics (Barcelona), documents the weight reduction associated with oleoyl estrone (OE) given orally over a 27-month period in a morbidly obese patient without dietary restrictions.

CEO and President, Leonard Firestone, MD, commented, "The careful observations reported in the medical literature were obtained during a 2-plus-year period, and therefore provide real support for oleoyl estrone's potential to meet the needs of obese...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2003-12-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry